Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Recruiting NCT07898683

A Phase I Study of Intra-Arterial Yttrium-90 Radioembolization for Unresectable Pancreatic Cancer

Conditions: Pancreatic Cancer Non-resectable

Sex: All

Ages: 18 Years – 75 Years

Healthy volunteers: No

Phase: PHASE1

Enrollment: 12

Sponsor: National Medical Research Radiological Centre of the Ministry of Health of Russia

Location: Medical Radiological Research Center named after A.F. Tsyb (MRRC) - National Medical Research Center of Radiology Obninsk

Summary

This clinical study aims to evaluate the safety and tolerability of intra-arterial Yttrium-90 (90Y) glass microspheres in patients with unresectable pancreatic adenocarcinoma. The study will assess radiation dose distribution, adverse effects, and preliminary efficacy following selective arterial radioembolization.

Eligibility Criteria

Inclusion Criteria: * Histologically confirmed pancreatic adenocarcinoma (T4N0/1M0/1) * ECOG performance status 0-1, for at least 2 weeks * Life expectancy ≥12 weeks * Signed informed consent for participation Exclusion Criteria: * ECOG \>2 or Karnofsky score \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07898683). StuddyBuddy aggregates publicly available trial information.